Drug neuroleptic action (options)

 

(57) Abstract:

The drug is made in the form of pills and is a combination of chlorpromazine and auxiliary substances. As auxiliary substances it contains, g: beeswax 0,00004 - 0,00005, gelatin 0,00018 - 0,00023, sugar of € 0.195 - 0,227, starch syrup 0,010 - 0,012, titanium dioxide 0,0023 - 0,0028 and talc 0,00004 - 0,00075. The content of chlorpromazine is, g: 0,023 - 0,027. Qualitative and quantitative composition of the drug is allowed to get a quality bean with the given therapeutic properties. 3 S. p. f-crystals.

The invention relates to medicine, in particular to drugs neuroleptic action.

Known drug, made in the form of pills, which is a combination of chlorpromazine and auxiliary substances (see M. D. Mashkovsky, "drugs", M, 1994, part 1, pages 58-61).

The task of the invention to provide quality bean with the given therapeutic properties.

The solution of this problem is achieved by the fact that the drug is made in the form of pills, which is a combination of chlorpromazine and auxiliary substances, as vspomogatelnaya ingredients was:

Chlorpromazine - 0,023 - 0,027

Beeswax - 0,00004 - 0,00005

Gelatin - 0,00018 - 0,00023

Sugar of € 0.195 - 0,227

Starch syrup - 0,010 - 0,012

Titanium dioxide - 0,0023 - 0,0028

Talc - 0,00004 - 0,00075

In the second embodiment, the drug is made in the form of pills, which is a combination of chlorpromazine and auxiliary substances, as auxiliary substances contains beeswax, gelatin, sugar, starch syrup, titanium dioxide, iron oxide and talc, with the following ratio of ingredients was:

Chlorpromazine - 0,046 - 0,054

Beeswax - of 0.00006 - 0,00007

Gelatin - 0,00026 - 0,00032

Sugar - 0,267 - 0,296

Starch syrup - 0,0147 - 0,0162

Titanium dioxide - 0,00196 - 0,00240

Iron oxide - 0,00042 - 0,00051

Talc - 0,00005 - 0,00105

In the third embodiment, the drug is made in the form of pills, which is a combination of chlorpromazine and auxiliary substances, as auxiliary substances contains beeswax, gelatin, sugar, starch syrup, iron oxide and talc, with the following ratio of ingredients was:

Chlorpromazine - 0,0925 - 0,1075

Beeswax - 0,00008 - 0,0001

Gelatin - 0,00037 - 0,00045

Sugar - 0,370 - 0,410

Starch syrup - 0, inasin is one of the main representatives of neuroleptics. One of the main features of the action of chlorpromazine on the Central nervous system is a strong sedative effect. Increases with the dose of chlorpromazine General sedation is accompanied by inhibition of the conditioned-reflex activity and primarily motor-defensive reflexes, reduced spontaneous motor activity and some relaxation of skeletal muscles, there comes a state of reduced responsiveness to exogenous stimuli, consciousness, however, remains. In high doses, can develop a state of sleep.

An important property of pills chlorpromazine is its blocking effect on Central adrenergic and dopaminergic receptors. The drug reduces or even eliminates the increase in blood pressure and other effects caused by adrenaline and adrenomimeticheskimi substances.

Using chlorpromazine can arrest the various psychomotor excitation, to weaken or completely arrest the delusions and hallucinations, reduce or remove the fear.

In psychiatric practice pills chlorpromazine used in a variety of States of agitation in patients with schizophrenia (hallucinatory-delusional, GEB.

The possibility of practical realization of the invention the following examples:

For the first option

Example 1

chlorpromazine - 0,0234 g

beeswax - 0,000048 g

gelatin - 0,000226 g

sugar - 0,2269 g

starch syrup - 0,0115 g

titanium dioxide - 0,00278 g

talc - 0,000745 g

Example 2

chlorpromazine - 0,269 g

beeswax - 0,000041 g

gelatin - 0,000184 g

sugar - 0,1951 g

starch syrup - 0,0105 g

titanium dioxide - 0,00233 g

talc - 0,000042 g

For the second option

Example 1

chlorpromazine - 0,0462 g

beeswax - 0,000068 g

gelatin - 0,000315 g

sugar - 0,2959 g

starch syrup - 0,01617 g

titanium dioxide - 0,00238 g

iron oxide - 0,000508 g

talc - 0,001047 g

Example 2

chlorpromazine - 0,0538 g

beeswax - 0,000062 g

gelatin - 0,000263 g

sugar - 0,2671 g

starch syrup - 0,01473 g

titanium dioxide - 0,00194 g

iron oxide - 0,000424 g

talc - 0,000053 g

For the third option

Example 1

chlorpromazine - 0,9252 g

beeswax - 0,00009 g

gelatin - 0,000447 g

sugar - 0,4099 g

starch syrup - 0,0277 g

iron oxide - 0,00389 g

talc - 0,0146 g

Example 2

chlorpromazine - 0,10747 g

wax p is 00323

talc - 0,000073 g

The production of tablets of chlorpromazine consists of the following stages:

1. Preparation of raw material

2. Preparation of syrups

3. Obtaining bean-cake mix

4. Getting pills chlorpromazine

5. Packing and packaging pills

Raw material preparation involves sifting sugar, grinding it on micromelia (sieve N 05) and passing through the magnets to trap impurities.

Preparation of syrups

Syrup 1. Ingredients: distilled water, granulated sugar, starch syrup, solids content (81,7 0,25)% refractive index 1,494 - 1,495, the content of inert sugar syrup should be (15,5 1,5)%. Syrup 1 is filtered through a sieve N 38 and a double layer of cheesecloth. Syrup 1 prepare watering syrup 16.

Syrup II. Ingredients: distilled water and sugar. The content of dry matter (66,5 1,5)%, the refractive index 1,435 - 1,462. Filter through a sieve N 38 and a double layer of gauze.

Syrup 1a (for drops of 0.025, 0.05 and 0.1). Ingredients: distilled water, syrup, substandard pills. The solids content (61 1)%, the refractive index 1,442 - 1,446. The syrup is filtered through a sieve N 38 and a double layer of gauze.

Syrup 1B (for drops of 0.025 and 0.05). Ingredients: syrup 1, distilled water. consistent water gelatin, titanium dioxide (for color 0,025 pills).

Syrup g Composition: same as syrup 1B with the addition of iron oxide (for drops 0,05).

Syrup 1D (for drops of 0.1). Ingredients: syrup 1B with the addition of titanium dioxide and iron oxide.

Getting pills chlorpromazine

Pills chlorpromazine make a method drazhirovanija.

The estimated amount of the sugar grains are loaded into the drageeing boiler and using a watering syrups and powdered sugar injected powder chlorpromazine in small portions with continuous rotation of the boiler. Received pills-prefabricated dry and after the analysis is performed layering sugar shell for a specific weight and size of the bean.

After drying spend staining the surface of the bean corresponding dyes and polishing.

1. The drug, made in the form of pills, which is a combination of chlorpromazine and excipients, characterized in that as auxiliary substances it contains beeswax, gelatin, sugar, starch syrup, titanium dioxide and talc in the following ratio of ingredients:

Chlorpromazine - 0,023 - 0,027

Beeswax - 0,00004 - 0,00005

Gelatin - 0,00018 - 0,0000075

2. The drug, made in the form of pills, which is a combination of chlorpromazine and excipients, characterized in that as auxiliary substances it contains beeswax, gelatin, sugar, starch syrup, titanium dioxide, iron oxide and talc in the following ratio of ingredients:

Chlorpromazine - 0,046 - 0,054

Beeswax - of 0.00006 - 0,00007

Gelatin - 0,00026 - 0,00032

Sugar - 0,267 - 0,296

Starch syrup - 0,0147 - 0,0162

Titanium dioxide - 0,00196 - 0,00240

Iron oxide - 0,00042 - 0,00051

Talc - 0,00005 - 0,00105

3. The drug, made in the form of pills, which is a combination of chlorpromazine and excipients, characterized in that as auxiliary substances it contains beeswax, gelatin, sugar, starch syrup, iron oxide and talc in the following ratio of ingredients:

Chlorpromazine - 0,0925 - 0,1075

Beeswax - 0,00008 - 0,0001

Gelatin - 0,00037 - 0,00045

Sugar - 0,370 - 0,410

Starch syrup - 0,024 - 0,028

Iron oxide - 0,0032 - 0,0039

Talc - 0,00007 - 0,015

 

Same patents:

The invention relates to pharmaceutical industry and relates to a solid pharmaceutical composition risedronate for oral administration
The invention relates to oral forms of administration of medicinal products on the basis of pantoprazole

The invention relates to the field of veterinary medicine, in particular veterinary gynecology, and can be used for the prevention and treatment of postpartum endometritis

The invention relates to a crystalline form of 7-[2-(2-amino - 1,3-thiazol-4-yl)-2-methoxyimino)acetamido] -3-[(FSD-2-ylcarbonyl) thiomethyl]-3-cefem-4-carboxylic acid (also known as 7-[2-(2-amino-4-thiazolyl)-2-methoxyimino)acetamido] -3-[2 - (uranilkarbonatov)-8-oxo-5-thia-1-azabicyclo[4,2,0] Oct-2-ene-1-carboxylic acid), also known as ceftiofur, formula 1 circuits in the formula next

The invention relates to pharmacology, and relates to new 5-thia-1,4-diazabicyclo[4.2.0]octane-3,8-dioxo-derivatives of the General formula 1

< / BR>
where R1represents hydrogen, halogen; R2represents hydrogen, halogen, amino, РhСН2СОNН, РhОСН2СОNН, phthalimido, the МеNНСОС6H4SLEEP, 3-o-chlorophenyl-5-METI-isoxazolyl-4-carbylamine; R3represents hydrogen, alkyl, benzyl, heterocyclic ring, for example, isoxazol, pyrazole; n is 1 or 2

The invention relates to new derivatives of hydroxamic acids, possessing valuable pharmacological properties, in particular showing the properties of an inhibitor of collagenase, which can be used to delay the development or prevention of diseases of degeneration of the joints, such as rheumatoid arthritis or osteoarthritis, or in the treatment of invasive tumors, atherosclerosis or multiple sclerosis, as well as the way they are received, intermediate products for their production, pharmaceutical preparation and method thereof
The invention relates to medicine, namely to intensive care

The invention relates to new compounds with dual activity, namely the activity of inhibiting angiotensin converting enzyme, and the activity of inhibiting neutral endopeptidase and to methods of producing these compounds
The invention relates to medicine, namely to the chemical-pharmaceutical industry and relates to a method of obtaining a tablet form of the drug

FIELD: organic synthesis.

SUBSTANCE: invention provides substituted 7-acylaminocephalosporins of formula I:

(I), where W denotes CH or B; V denotes NO; R1 hydrogen or С14-alkyl; R3 hydrogen or ester residue; and R2 one of the following groups: , , , , in which X, R5, R6, R'6, R7, and Hal have meanings indicated in claims, in free state, in the form of salts and/or solvates, or, if such forms are stable, in the form of internal salt, quaternary salt, or their hydrates, possessing antimicrobial activity. Invention also discloses a method for preparing such compounds and a pharmaceutical connected containing them.

EFFECT: increased choice of antimicrobial preparations.

13 cl, 10 tbl, 225 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to new derivatives of phenylpiperazine of the formula (I): , wherein X represents 1) group of the formula (1): , wherein S1 means hydrogen, halogen atom; S2 and S3 mean independently of one another hydrogen atom, (C1-C6)-alkyl, phenyl or benzyl; S4 means two hydrogen atoms, oxo-group; S5 means hydrogen atom (H), (C1-C4)-alkyl; Y means CH2, oxygen atom (O), sulfur atom (S); or 2) group of the formula (2): , wherein S1 has above given values; R means hydrogen atom (H), (C1-C4)-alkyl, (C2-C6)-alkoxyalkyl, (C2-C4)-alkenyl or (C2-C4)-alkynyl; or 3) group of the formula (3): wherein S1 has above given values; Z means CH2, oxygen atom (O), nitrogen atom (N); or 4) group of the formula (4): , wherein S1 has above given values; or 5) group of the formula (5): , wherein S1 has above given values; A means oxygen atom (O), nitrogen atom (N) linked with piperazine ring at position 5 or 8; or 6) group of the formula (6): , wherein S1 has above given values; S6 and S7 mean hydrogen atom or oxo-group; or 7) group of the formula (7): , wherein one of dotted line can represent a double bond; S1 has above given values; P = T = Q mean nitrogen atom or P = T mean nitrogen atom; Q means CH or CH2; or P = Q mean nitrogen atom; T means CH, CH2, CH-CH3, C-CH3; or P means nitrogen atom; T means CH, CH2; Q represents sulfur atom; m = 2-6; n = 0-2; R5 and R6 mean independently of one another hydrogen atom (H), (C1-C3)-alkyl; or R5 + R6 represent group -(CH2)p- wherein p = 3-5; R7 means (C1-C3)-alkyl, (C1-C3)-alkoxy-, halogen atom, cyano-group; or R6 + R7 (R7 at position 7 of indole ring) mean group -(CH2)q wherein q = 2-4, and their salts. Compound of the formula (I) elicit high affinity both to dopamine D2-receptor and to serotonin reuptake site that allows their applying in treatment of the central nervous system diseases.

EFFECT: valuable medicinal properties of compounds.

5 cl, 3 tbl, 4 sch, 8 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to new biologically active benzoxazine compounds and describes derivatives of benzoxazine of the following structure: wherein X1 and X2 are taken independently among hydrogen atom (H), -OR4, -CH2OR4; or X1 and X2 taken in common represent -O-CR

52
O- or -O-CR52
CR52
O-, or -O-CR52
=CR52
O-; Z represents oxygen atom (O) or sulfur atom (S); each R1 represents independently hydrogen atom (H) or (C1-C6)-alkyl; each R2 represents independently hydrogen atom (H) or (C1-C6)-alkyl, (C1-C3)-fluoroalkyl; each R4 represents independently hydrogen atom (H) or (C1-C6)-alkyl; each R5 represents hydrogen atom (H) or (C1-C6)-alkyl; n = 2, 3 or 4. Also, invention describes a method for preparing compound by cl. 1 with enantiomeric excess above 80% and relates to pharmaceutical composition for enhancing the synaptic response mediated by AMPA-receptors based on compounds by cl. 1. Pharmaceutical composition is useful for treatment of schizophrenia, schizophrenia-like behavior or depression in humans in necessary for carrying out such treatment based on compounds by cl. 1 wherein this pharmaceutical composition is useful for the memory improvement and comprising compound by cl. 1. Invention provides preparing new compounds eliciting useful biological properties.

EFFECT: valuable medicinal properties of compounds.

107 cl, 2 dwg, 2 tbl, 10 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of aryl carboxylic acids and describes a compound of the formula (I):

, wherein groups R1, R2, R3, R4 and groups R5 and R6 when they are joined to carbon atom can be similar or different and mean hydrogen, halogen atom, hydroxy-group or optionally substituted group taken among alkyl, alkoxy-group, phenyl, carboxylic acid or sulfonic acid; one or both substitutes R5 and R6 can mean oxo-group also if they are joined to carbon atom; if R5 and R are joined to nitrogen atom then they mean hydrogen atom, hydroxy-group or optionally substituted alkyl or benzyl; X means heteroatom taken among oxygen and sulfur atom or NH; Ar means optionally substituted bivalent a single or condensed aromatic or heterocyclic group wherein aromatic ring represents phenyl, naphthyl and heterocyclic group represents furan; R7 means hydrogen, halogen atom, alkoxy-group, alkyl, or it forms a bond with the adjacent group R8; R8 means hydrogen atom, hydroxy-, alkoxy-group, alkyl or optionally substituted benzyl; or R8 forms a bond in common with R7; R9 means hydrogen atom or optionally substituted group taken among alkyl, phenyl or benzyl group; R10 means hydrogen atom or optionally substituted group taken among alkyl, phenyl or benzyl group; Y means oxygen atom or NR12 wherein R12 means hydrogen atom, alkyl or benzyl; R10 and R12 can form in common five- or six-membered cyclic structure comprising carbon atoms that involves optionally one or some heteroatoms taken among oxygen, sulfur or nitrogen atoms; a binding group represented by the formula: -(CH2)n-(O)m- can be joined through nitrogen atom or through carbon atom and wherein n means a whole number from 1 to 4; m means a whole number from 0 to 1 under condition that when a binding group is joined through carbon atom then R5 either R6 represents oxo-group; Y means oxygen atom; R9 doesn't mean hydrogen atom; or its derivatives, analogs, its tautomeric forms, its stereoisomers, its polymorphic forms, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates. Also, invention describes methods for preparing compounds of the general formula (I), intermediate compounds and methods for their preparing, a pharmaceutical composition eliciting activity with respect to hPPRα, hPPRγ and inhibitory activity with respect to HMG-CoA-reductase and involving compound of the formula (I). Also, invention relates to methods for prophylaxis and treatment of different diseases caused by above said activity, a method for reducing the total cholesterol level and a method for reducing the glucose level. Invention provides preparing new compounds eliciting valuable biological properties.

EFFECT: improved preparing methods, valuable medicinal properties of compounds.

27 cl, 64 ex

FIELD: medicine, antibiotics.

SUBSTANCE: invention relates to cephalosporin antibiotic - cefuroximaxetil that is used in treatment of bacterial infections. Invention proposes a new form of cefuroximaxetil not forming gel in contact with an aqueous solution. New form represents a solid solution of cefuroximaxetil in polymer and/or solid dispersion on adsorbent. New form of cefuroximaxetil can be used for preparing a granulate that can be used in oral pharmaceutical compositions as tablets or powder. Exclusion of gel-formation allows improving solubility of cefuroximaxetil that results to enhancing absorption of cefuroximaxetil in digestive tract.

EFFECT: improved pharmaceutical properties of combinations.

23 cl, 3 dwg, 8 tbl, 19 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new imidazoquinolines of the formula (1): wherein R, R1, R2 and n have values given in the description. Compounds elicit effect of immunomodulating agents inducing biosynthesis of cytokines in animals in treatment of different pathologies, among them viral and neoplastic diseases. Also, invention relates to a pharmaceutical preparation used for inducing interferon-α or tumor necrosis α-factor, to a method for inducing biosynthesis of cytokines in animals and to methods for treatment of viral diseases and neoplasm pathologies in animals. Invention provides preparing new biologically active compounds.

EFFECT: improved inducing method, valuable properties of compounds and pharmaceutical preparation.

23 cl, 10 tbl, 231 ex

FIELD: medicine, phthisiology.

SUBSTANCE: one should lymphotropically introduce the mixture of 5.0 ml 0.25%-novocaine solution and 2.0 ml 1%-dioxidine solution or the mixture of 5.0 ml 0.25%-novocaine solution and 0.5 g cefazoline subcutaneously into jugular cavity and deeply behind xiphoid process, successively 1 point once daily, 5-7 injections/course. After injection the site of injection should be treated either with heparin ointment or ultrasound (1-3 MHz, PPM 0.2 W/sq. cm, for 2 min, through Vaseline oil) followed by evaluating roentgenological dynamics of the process 10-14 d later.

EFFECT: higher efficiency of differential diagnostics.

3 ex

FIELD: organic chemistry, biochemistry.

SUBSTANCE: invention relates to substituted derivatives of N-phenyl-2-hydroxy-2-methyl-3,3,3-trifluoropropaneamide of the formula (I): wherein n = 1 or 2; R1 represents chlorine, fluorine, bromine atom, methyl or methoxy-group; R2 is taken among of one the following groups: (i) halogen atom, nitro-, hydroxy- amino- or cyano-group; (ii) -X1-R5 wherein X1 represents -O-, -S-, -SO-, -SO2-, NR6-, -CO-, -CONR6-, -NR6CO- wherein R6 represents hydrogen atom and R5 is taken among (C1-C6)-alkyl optionally substituted with one or some A, and so on; (iii) 4-8-membered heterocyclic group joined by nitrogen atom that represents saturated monocyclic ring comprising 4-8 carbon atoms among that at least one is nitrogen atom and so on; R3 represents (C1-C6)-alkyl optionally substituted with one or some A and so on; A is taken among hydroxy-, amino-group, halogen atom, carboxy-, N-(C1-C4-alkyl)-amino-, N,N-di-(C1-C4-alkyl)-amino-group, carbamoyl and (C1-C6)-alkoxy-group; D is taken among: (i) -Xa-Rc wherein Xa represents -SO2, -CO-, -NRdCO-, -NRd- or -CONRd-; (iv) cyano-group or halogen atom; (v) -XcRf wherein Xc represents -C(O)- and Rf represents 4-8-membered heterocyclic group joined by nitrogen atom that represents saturated monocyclic ring comprising 4-8 carbon atoms among that at least one is nitrogen atom with optionally additional heteroatom taken independently among oxygen atom (O), optionally substituted at ring carbon atom by the hydroxy-group, halogen atom, (C1-C4)-alkoxy-group, (C1-C4)-alkyl or cyano-group; G represents (C1-C6)-alkanoyl; R4 represents hydrogen or fluorine atom; or to its pharmaceutically acceptable salt or its ester hydrolyzed in vivo. Also, invention proposes a method for preparing compound of the formula (I). Also, invention proposes pharmaceutical composition enhancing activity of pyruvate dehydrogenase comprising substituted derivatives of N-phenyl-2-hydroxy-2-methyl-3,3,3-trifluoropropaneamide of the formula (I) or its pharmaceutically acceptable salt or ester hydrolyzed in vivo in combination with pharmaceutically acceptable vehicle or carrier. Invention provides preparing derivatives of N-phenyl-2-hydroxy-2-methyl-3,3,3-trifluoropropaneamide enhancing activity of pyruvate dehydrogenase.

EFFECT: valuable medicinal and biochemical properties of compounds.

14 cl, 1 tbl, 85 ex

Up!